Promising Response Data for Menin Inhibitor in Relapsed/Refractory AML

(MedPage Today) — HOUSTON — Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor.
A pooled analysis of data from…

Source link : https://www.medpagetoday.com/meetingcoverage/soho/117333

Author :

Publish date : 2025-09-05 18:48:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Promising Response Data for Menin Inhibitor in Relapsed/Refractory AML

Does Eating Red Meat Actually Raise Your Cancer Risk?

Trump Admin Investigates Medicaid Spending on Immigrants in Democratic States

Related Posts

More Kids Have High Blood Pressure, Many May Be Missed by In-Office Screening Alone

At Hush-Hush MAHA Summit, Vance Praises RFK Jr. for Defying Convention

Seladelpar Eases PBC-Related Itch for 30 Months

Rapid-Acting Drug for Major Heart Attacks Hits Main Goal in Trial

Something Off About Recent Heart Failure Stem Cell Trial, Major Journal Admits

Hospitals knew a heart device led to more patients’ deaths

More Kids Have High Blood Pressure, Many May Be Missed by In-Office Screening Alone

At Hush-Hush MAHA Summit, Vance Praises RFK Jr. for Defying Convention

Seladelpar Eases PBC-Related Itch for 30 Months

Rapid-Acting Drug for Major Heart Attacks Hits Main Goal in Trial

Something Off About Recent Heart Failure Stem Cell Trial, Major Journal Admits

Hospitals knew a heart device led to more patients’ deaths

Adults 50-64 Should be Exempt From Medicaid Work Requirements

Psych Telehealth Prescribing Extension; Jennifer Lawrence’s PPD; Youth Turn to AI

Categories

Archives